9.10
0.13 (1.45%)
| Penutupan Terdahulu | 8.97 |
| Buka | 8.83 |
| Jumlah Dagangan | 163,348 |
| Purata Dagangan (3B) | 516,862 |
| Modal Pasaran | 564,455,744 |
| Harga / Buku (P/B) | 3.95 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.750 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.35% |
| Nisbah Semasa (MRQ) | 17.23 |
| Aliran Tunai Operasi (OCF TTM) | -42.28 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -30.45 M |
| Pulangan Atas Aset (ROA TTM) | -15.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -19.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | GH Research PLC | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 2.0 |
| Purata | 2.00 |
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 33.88% |
| % Dimiliki oleh Institusi | 52.11% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 32.00 (Guggenheim, 251.65%) | Beli |
| 32.00 (Stifel, 251.65%) | Beli | |
| Median | 31.50 (246.15%) | |
| Rendah | 14.00 (Cantor Fitzgerald, 53.85%) | Beli |
| Purata | 27.25 (199.45%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 11.59 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 13 Mar 2025 | 32.00 (251.65%) | Beli | 10.88 |
| RBC Capital | 07 Mar 2025 | 31.00 (240.66%) | Beli | 10.50 |
| Stifel | 27 Feb 2025 | 32.00 (251.65%) | Beli | 10.65 |
| Cantor Fitzgerald | 13 Feb 2025 | 14.00 (53.85%) | Beli | 14.31 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Feb 2025 | Pengumuman | GH Research Reports Full Year 2024 Financial Results and Provides Business Updates |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |